Athersys (NASDAQ:ATHX) will announce its earnings results after the market closes on Wednesday, August 7th.
Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.09). The business had revenue of $1.45 million during the quarter. Athersys had a negative return on equity of 58.10% and a negative net margin of 109.78%.
Athersys stock opened at $1.32 on Tuesday. The company’s 50-day moving average price is $1.58. Athersys has a 52-week low of $1.28 and a 52-week high of $2.23.
In related news, insider William Lehmann, Jr. sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $1.80, for a total transaction of $36,000.00. Following the completion of the transaction, the insider now directly owns 574,952 shares in the company, valued at approximately $1,034,913.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 15.31% of the company’s stock.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.